Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Rattus norvegicus | Type-1A angiotensin II receptor | Starlite/ChEMBL | No references |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
%max (binding) | = 3.6 % | Agonist activity at Homo sapiens (human) PPARgamma LBD expressed in African green monkey CV-1 cells co-expressing GAL4 assessed as beta-galactosidase activity at 10 uM after 24 hr by luciferase reporter gene assay relative to rosiglitazone | ChEMBL. | No reference |
Inhibition (binding) | = 40 % | Displacement of [125I]-SI-Ang-2 from AT1 receptor in Rattus norvegicus Sprague-Dawley (rat) liver membranes at 10 uM after 2 hr | ChEMBL. | No reference |
Ki (binding) | > 10000 nM | Displacement of [125I]-SI-Ang-2 from AT1 receptor in Rattus norvegicus Sprague-Dawley (rat) liver membranes after 2 hr | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.